104 related articles for article (PubMed ID: 22206859)
1. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients.
Su W; Chen HB; Li SH; Wu DY
Clin Neurol Neurosurg; 2012 May; 114(4):372-5. PubMed ID: 22206859
[TBL] [Abstract][Full Text] [Related]
2. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
3. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
[TBL] [Abstract][Full Text] [Related]
4. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas.
Brommeland T; Rosengren L; Fridlund S; Hennig R; Isaksen V
Acta Neurol Scand; 2007 Dec; 116(6):380-4. PubMed ID: 17986096
[TBL] [Abstract][Full Text] [Related]
6. Enteric GFAP expression and phosphorylation in Parkinson's disease.
Clairembault T; Kamphuis W; Leclair-Visonneau L; Rolli-Derkinderen M; Coron E; Neunlist M; Hol EM; Derkinderen P
J Neurochem; 2014 Sep; 130(6):805-15. PubMed ID: 24749759
[TBL] [Abstract][Full Text] [Related]
7. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
[TBL] [Abstract][Full Text] [Related]
8. Exposure to methyl mercury results in serum autoantibodies to neurotypic and gliotypic proteins.
el-Fawal HA; Gong Z; Little AR; Evans HL
Neurotoxicology; 1996; 17(1):267-76. PubMed ID: 8784838
[TBL] [Abstract][Full Text] [Related]
9. Exposure to methylmercury results in serum autoantibodies to neurotypic and gliotypic proteins.
el-Fawal HA; Gong Z; Little AR; Evans HL
Neurotoxicology; 1996; 17(2):531-9. PubMed ID: 8856747
[TBL] [Abstract][Full Text] [Related]
10. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
11. Rapid immunoassay for the determination of glial fibrillary acidic protein (GFAP) in serum.
Vissers JL; Mersch ME; Rosmalen CF; van Heumen MJ; van Geel WJ; Lamers KJ; Rosmalen FM; Swinkels LM; Thomsen J; Herrmann M
Clin Chim Acta; 2006 Apr; 366(1-2):336-40. PubMed ID: 16405937
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of Human Traumatic Spinal Cord Injury.
Ahadi R; Khodagholi F; Daneshi A; Vafaei A; Mafi AA; Jorjani M
Spine (Phila Pa 1976); 2015 Jul; 40(14):E823-30. PubMed ID: 25341992
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke.
Dvorak F; Haberer I; Sitzer M; Foerch C
Cerebrovasc Dis; 2009; 27(1):37-41. PubMed ID: 19018136
[TBL] [Abstract][Full Text] [Related]
14. Glial fibrillary acidic protein: a marker of axonal Guillain-Barrè syndrome and outcome.
Notturno F; Caporale CM; De Lauretis A; Uncini A
Muscle Nerve; 2008 Jul; 38(1):899-903. PubMed ID: 18508349
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of chemokines in Parkinson's disease.
Scalzo P; de Miranda AS; Guerra Amaral DC; de Carvalho Vilela M; Cardoso F; Teixeira AL
Neuroimmunomodulation; 2011; 18(4):240-4. PubMed ID: 21430395
[TBL] [Abstract][Full Text] [Related]
16. Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.
Sun CC; Luo FF; Wei L; Lei M; Li GF; Liu ZL; LE WD; Xu PY
Chin Med J (Engl); 2012 Feb; 125(4):583-7. PubMed ID: 22490478
[TBL] [Abstract][Full Text] [Related]
17. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.
Trysberg E; Nylen K; Rosengren LE; Tarkowski A
Arthritis Rheum; 2003 Oct; 48(10):2881-7. PubMed ID: 14558094
[TBL] [Abstract][Full Text] [Related]
18. [Immunochemical correlates of the severity of Parkinson's disease].
Morozov SG; Ivanova-Smolenskaia IA; Markova ED; Piradov MA; Poleshchuk VV; Labunskiĭ DA; Gnedenko BB
Vopr Med Khim; 1997; 43(1):34-8. PubMed ID: 9281224
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies to neurotypic and gliotypic proteins as biomarkers of neurotoxicity: assessment of trimethyltin (TMT).
El-Fawal HA; O'Callaghan JP
Neurotoxicology; 2008 Jan; 29(1):109-15. PubMed ID: 18001836
[TBL] [Abstract][Full Text] [Related]
20. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase.
Honda M; Tsuruta R; Kaneko T; Kasaoka S; Yagi T; Todani M; Fujita M; Izumi T; Maekawa T
J Trauma; 2010 Jul; 69(1):104-9. PubMed ID: 20093985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
